Thursday 1 August 2019

Drug Duo May Be a Weapon Against a Common Leukemia

aml cancer cells

The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic leukemia (CLL) found that a combination of rituximab and ibrutinib extended patient survival.



from WebMD Health https://ift.tt/2YFE9nO

0 comments:

Post a Comment